Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe. The company has enclosed its press release.
The above information is a part of company’s filings submitted to BSE.